Status: Recruiting
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children
Participants needed: 60
Trial details
Age: 3-18Biological sex: AllType: InterventionalSponsor: Zhu XiaofanUpdated: Apr 9, 2024Locations: 2
Eligibility criteria
Recurrence during chemotherapy, early recurrence after drug withdrawal (<12 mont... [+6]
1, severe cardiac insufficiency, left ventricular ejection fraction <50%;